GLS Pharma Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U24239TS2004PLC184306 Incorporated 01 September 2004 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Public Limited Company pharma MSME · Small
Revenue · FY 2023
₹36.08 Cr
▲ 13862% YoY
Net profit · FY 2023
₹1.9 Cr
Net margin 5.3%
EBITDA · FY 2023
₹5.27 Cr
EBITDA margin 14.6%
Authorised capital
₹1.3 Cr
Registered with MCA
Paid-up capital
₹1.2 Cr
Issued & subscribed
Open charges
₹2 Cr
Satisfied ₹15.83 Cr
Company age
22 yrs
Est. 2004
Employees · EPFO
133
Provident fund records

About GLS Pharma Limited

Data last updated:

GLS Pharma Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Aurobindo Pharma Ltd. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 September 2004 and has been in existence for over 22 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TS2004PLC184306. Its GSTIN is 36AACCG2082K1ZK (Telangana). The company holds 8 GST registrations, of which 5 are active.

The company has an authorised share capital of ₹1.3 Cr and a paid-up capital of ₹1.2 Cr. It was formerly known as Gls Pharma Private Limited and Getwell Life Sciences India Private Limited. It is led by directors including Srinivasa Ramachandra Rao Ilapakurthy and Ravikiran Namburi.

Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1, Hyderabad Knowledge City Raidurg Panmaktha, Telangana, India – 500032.

As per the financials filed for FY 2023, the company reported a revenue of ₹36.08 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹1.9 Cr (net margin 5.3%) and EBITDA of ₹5.27 Cr (EBITDA margin 14.6%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 16% over five years.

The company has about 133 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: GLS Pharma. As per MCA filings, the company has open charges of ₹2 Cr and satisfied charges of ₹15.83 Cr on record. Court records list 11 cases involving the company, including 11 filed against it; 2 cases are pending. The company has 7 deals on record (4 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹88 Lakh; the latest was in August 2022. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 smaller; the largest is Filbs Nutra Private Limited with revenue of ₹25.79 Lakh. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 238 overdue payments to 81 micro and small suppliers.

GLS Pharma Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-08-0011824). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glspharma.com.

Company details

CIN U24239TS2004PLC184306
Registration Number 184306
Incorporation Date 01 September 2004
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Parent Company Aurobindo Pharma Ltd
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-DL-08-0011824

Name history

GLS Pharma has undergone 2 name changes throughout its history. The company was previously known as Gls Pharma Private Limited, and Getwell Life Sciences India Private Limited.. The current legal name is Gls Pharma Limited.

Company NameStatus
GLS Pharma LimitedCurrent
Gls Pharma Private LimitedPrevious
Getwell Life Sciences India Private Limited.Previous

CIN history

GLS Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24239TS2004PLC184306, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24239TS2004PLC184306Current
U24239DL2004PTC128728Previous
U24239DL2004PLC128728Previous

Recognitions & Rankings of GLS Pharma

MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-DL-08-0011824

Contact details

GLS Pharma Limited's registered office is in Hyderabad, Telangana. Its website is glspharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1, Hyderabad Knowledge City Raidurg Panmaktha, Telangana, India – 500032
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of GLS Pharma Limited, buy the company report.

Comprehensive company report
GLS Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

GLS Pharma operates one associated brand: GLS Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Oncology APIs and anti-cancer products are manufactured.glspharma.com

Financials of GLS Pharma Limited

FY 2025 filings available

GLS Pharma Limited reported revenue of ₹36.08 Cr (up 13862% YoY) for FY 2023.

Revenue · FY 2023
₹36.08 Cr ▲ 13862%
Net profit · FY 2023
₹1.9 Cr margin 5.3%
EBITDA · FY 2023
₹5.27 Cr margin 14.6%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
3 years · compounded
▲ 11%
5 years · compounded
▲ 16%
EBITDA CAGR growth
3 years · compounded
▲ 33%
5 years · compounded
▲ 26%

Revenue has grown at a compounded annual rate (CAGR) of 16% over five years. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profit and Loss Statement
Revenue from Operations₹36.08 Cr
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹5.27 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹1.9 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profitability
EBITDA Margin14.6%
Net Profit Margin5.3%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of GLS Pharma Limited, buy the company report.

Board of directors of GLS Pharma Limited

GLS Pharma has 3 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Srinivasa Ramachandra Rao IlapakurthyDirector15 Dec 20232 Years 11 MonthsCurrent
Pendem Harish BabuAdditional Director25 Oct 20251 Years 0 MonthsCurrent
Ravikiran NamburiDirector20 Sep 20242 Years 1 MonthsCurrent

Peer comparison

GLS Pharma Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
GLS Pharma Limitedthis company₹36.08 Cr (FY 2023)₹1.9 Cr5.3%13862.0%133Hyderabad, Telangana, India
Filbs Nutra Private Limited₹25.79 Lakh (FY 2018)-14.0%Udaipur, Rajasthan, India
Shree Govardhan Pharma Private Limited₹25.75 Lakh (FY 2025)774.0%Jaipur, Rajasthan, India
Austin Lifesciences Private Limited₹25.74 Lakh (FY 2022)-48.0%Pune, Maharashtra, India
Kigo Pharma Private Limited₹25.72 Lakh (FY 2024)7.0%Telangana, India

To see the full peer comparison of GLS Pharma Limited, buy the company report.

Auditor

GLS Pharma Limited is audited by G P M & ASSOCIATES for the financial year 2023.

Auditor firmFinancial yearFirm registration number
G P M & ASSOCIATESFY 2023015343S

Shareholding

The shareholding of GLS Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023FY 2022FY 2021FY 2020FY 2019
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of GLS Pharma Limited, buy the company report.

Charges & borrowings

Open charges
₹2 Cr
Satisfied charges
₹15.83 Cr
Breakdown by lending institutions
Canara Bank₹2.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
20 Sep 2022100616943Canara Bank₹2 CrOpen
30 Aug 2021100492779Canara Bank₹2.5 CrSatisfied
15 Dec 2020100411450Syndicate Bank₹96 LakhSatisfied
14 Dec 2020100411449Canara Bank₹80 LakhSatisfied
30 Sep 201510603903Syndicate Bank₹7.97 CrSatisfied

To see the full charge records of GLS Pharma Limited, buy the company report.

Total charge records: 8 View all charges

Deals & funding

GLS Pharma Limited has 7 deals on record (4 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹88 Lakh; the latest was in August 2022.

Total deals
7
Funding rounds
4
Secondary share transfers
2
Acquisition
1
Disclosed funding
₹88 Lakh

Deals on record (5 of 7)

WhenDealAmountParties
Aug 2022Acquisition₹28.05 CrBuyer: Aurobindo Pharma Ltd
Nov 2017Funding round₹10 LakhInvestors: an individual
Sep 2016Secondary share transferUndisclosedBuyer: an individual
Seller: 2 individuals
Mar 2012Secondary share transferUndisclosedBuyer: 4 individuals
Seller: 2 individuals
Dec 2011Funding round₹28 LakhInvestors: 2 individuals

To see the full deal history of GLS Pharma Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

GLS Pharma Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 238 overdue payments to 81 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 81)

SupplierAmount dueDue sinceReported on
Obvez Labs Private Limited
Levim Biotech LLP
Avanscure Lifesciences Private Limited
Bo-Chem Private Limited
Adley Lab Limited

To see the full MSME payment records of GLS Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

GLS Pharma Limited has a workforce of 133 employees on its EPFO records as of May 2026, across 2 active EPFO establishments.

Employee count
133
Active EPFO establishments
2
Employee growth
-4.3%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27133
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of GLS Pharma Limited, buy the company report.

GST

GLS Pharma has 8 GST registrations: 5 active and 3 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
8
Active
5
Cancelled / inactive
3
GSTINStateStatusRegistered on
36AACCG2082K1ZKTelanganaActive01 Jul 2017
07AACCG2082K1ZLDelhiActive01 Jul 2017
33AACCG2082K1ZQTamil NaduActive08 Nov 2017
18AACCG2082K1ZIAssamActive08 Feb 2018

To see the full GST registrations and return filing status of GLS Pharma Limited, buy the company report.

Recent activity

GLS Pharma Limited has 22 board changes on record since 2010: 3 appointments and 19 cessations. The latest: Pendem Harish Babu was appointed as Additional Director on 25 Oct 2025.

Appointed
Pendem Harish Babu was appointed as Additional Director.
AGM
Gls Pharma Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Ceased
Ravikiran Namburi ceased to be Additional Director.
Ceased
Godi Bhaskara Reddy ceased to be Additional Director.
Charges
A charge with Canara Bank of Rs. 2.00 Cr registered on 20 Sep 2022 with Charge ID 100616943 was modified on 18 Jun 2025.
Filing
Gls Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge registered on 11 Jan 2007 via Charge ID 10033531 with Icici Bank Limited was fully satisfied on 20 Jan 2025.
Appointed
Ravikiran Namburi was appointed as Director.
Ceased
Srinivasa Ramachandra Rao Ilapakurthy ceased to be Additional Director.
Ceased
Venkatanarayana Reddy Jayampu ceased to be Additional Director.
Appointed
Srinivasa Ramachandra Rao Ilapakurthy was appointed as Director.
Ceased
Debashis Sarkar ceased to be Additional Director.

29 earlier events are in the company report.

Frequently asked questions

GLS Pharma is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 September 2004 (22+ years old) and is registered under CIN U24239TS2004PLC184306.

GLS Pharma has 3 current directors:

The latest financial statements of GLS Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of GLS Pharma is 36AACCG2082K1ZK, registered in Telangana. The company has 8 GST registrations in all, of which 5 are active and 3 are cancelled or inactive. Other active GSTINs include 07AACCG2082K1ZL (Delhi), 33AACCG2082K1ZQ (Tamil Nadu), 18AACCG2082K1ZI (Assam).

The CIN (Corporate Identification Number) of GLS Pharma is U24239TS2004PLC184306. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

GLS Pharma has 11 court cases on record: 11 filed against it. 2 are pending. Most are in the high courts.

GLS Pharma was incorporated on 01 September 2004, making it 22+ years old. It is registered with the Registrar of Companies, Hyderabad.

GLS Pharma has 7 deals on record (4 funding rounds, 2 secondary share transfers, 1 acquisition), with disclosed funding of ₹88 Lakh; the latest was in August 2022.

The peers of GLS Pharma by revenue are Filbs Nutra Private Limited, Shree Govardhan Pharma Private Limited, Austin Lifesciences Private Limited, Kigo Pharma Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Pendem Harish Babu was appointed as Additional Director on 25 Oct 2025. Ravikiran Namburi ceased to be Additional Director on 21 Sep 2025. Godi Bhaskara Reddy ceased to be Additional Director on 19 Aug 2025. GLS Pharma has 22 board changes on record in total.

Yes, GLS Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-DL-08-0011824).

GLS Pharma has 12 MSME Form 1 returns on record between 2019 and 2024, listing 238 overdue payments to 81 micro and small suppliers. The latest return was filed on 30 Apr 2024.